Long-Term Erythropoietin Therapy Does Not Affect Metalloproteinases and Their Inhibitor Levels, Oxid...
Long-Term Erythropoietin Therapy Does Not Affect Metalloproteinases and Their Inhibitor Levels, Oxidative Stress and Inflammation in Hemodialyzed Patients
About this item
Full title
Author / Creator
Publisher
Basel, Switzerland: S. Karger AG
Journal title
Language
English
Formats
Publication information
Publisher
Basel, Switzerland: S. Karger AG
Subjects
More information
Scope and Contents
Contents
Background: Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) play an important role in the atherosclerosis. Recombinant human erythropoietin (EPO) has become widely used to treat anemic hemodialyzed (HD) patients; however, an increased mortality has been reported for HD patients with cardiovascular disease when randomly assigned...
Alternative Titles
Full title
Long-Term Erythropoietin Therapy Does Not Affect Metalloproteinases and Their Inhibitor Levels, Oxidative Stress and Inflammation in Hemodialyzed Patients
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_karger_primary_101191
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_karger_primary_101191
Other Identifiers
ISSN
0250-8095
E-ISSN
1421-9670
DOI
10.1159/000101191
